Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 1,682 | 45% |
| 2020 | 13 | 1,607 | 51% |
| 2021 | 16 |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Michigan; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 59 | 5,586−14%/yr | −14%/yr | 6.91.7× | 71% | 4,770 in 2030−2.6%/yr |
| Peripheral arterial intervention |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
| 2024 |
| 1,534 |
| 66% |
| 2025 est. | ≈ 1,580 | – |
| 2026 est. | ≈ 1,640 | – |
| 1,843 |
| 55% |
| 2022 | 12 | 1,714 | 59% |
| 2023 | 11 | 1,560 | 63% |
| 2024 | 10 | 1,534 | 66% |
| 2025 from claims | – | 1,585 1,454–1,677 | 67% |
| 2026 forecast | – | 1,636 1,439–1,888 | 67% |
| 2027 forecast | – | 1,671 1,428–1,991 | 68% |
| 2028 forecast | – | 1,705 1,423–2,088 | 69% |
| 2029 forecast | – | 1,739 1,421–2,181 | 70% |
| 2030 forecast | – | 1,773 1,421–2,272 | 70% |
In 2025, 80% inpatient hospital, 2% hospital outpatient, 18% office. The share outside the hospital has moved −17 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 1,351−4.1%/yr |
| −4.1%/yr |
| 1.2 |
| 0% |
| 1,470 in 2030+1.4%/yr |
| Indiana | 7 | 1,264+6.5%/yr | +6.5%/yr | 1.8 | 15% | 1,940 in 2030+7.4%/yr |
| Missouri | 8 | 855−5.5%/yr | −5.5%/yr | 1.4 | 0% | 790 in 2030−1.3%/yr |
| Wisconsin | 1 | 601−4.2%/yr | −4.2%/yr | 1.1 | 5% | 1,010 in 2030+9.1%/yr |
| Minnesota | 3 | 534−2.8%/yr | −2.8%/yr | 1.2 | 0% | 1,150 in 2030+14%/yr |
| Kansas | 2 | 454+4.3%/yr | +4.3%/yr | 1.1 | 0% | 920 in 2030+12%/yr |
| South Dakota | 6 | 318+3.2%/yr | +3.2%/yr | 2.5 | 0% | 220 in 2030−5.7%/yr |
| Iowa | 1 | 3090%/yr | 0%/yr | 0.7 | 0% | 490 in 2030+8.2%/yr |
| Nebraska | 1 | 272−1.9%/yr | −1.9%/yr | 1.1 | 0% | 220 in 2030−3.7%/yr |
| North Dakota | 1 | 126−1.2%/yr | −1.2%/yr | 1.3 | 0% | 260 in 2030+13%/yr |
| 34 |
| 4,986−13%/yr |
| −13%/yr |
| 5.61.4× |
| 65% |
| 5,540 in 2030+1.8%/yr |
| Superficial venous ablation | 44 | 2,935−15%/yr | −15%/yr | 3.31.0× | 95% | 2,850 in 2030−0.5%/yr |
| Carotid revascularization | 13 | 961−9.4%/yr | −9.4%/yr | 1.11.0× | 0% | 870 in 2030−1.7%/yr |
| Aortic endografts (EVAR/TEVAR) | 0 | 381−11%/yr | −11%/yr | 0.51.0× | 0% | 370 in 2030−0.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Stryker leads with 68% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 13 companies reported engagement with Michigan’s surgeons worth $555K in consulting, speaking, meals and travel tied to these products, about $56K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.